Rana F Hamdy1, Alice J Hsu2, Chris Stockmann3, Jared A Olson4, Matthew Bryan5,6, Adam L Hersh3, Pranita D Tamma7, Jeffrey S Gerber5,6. 1. Department of Pediatrics, Children's National Health System, Washington, DC; rhamdy@childrensnational.org. 2. Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland. 3. Department of Pediatrics, University of Utah, Salt Lake City, Utah. 4. Department of Pharmacy, Primary Children's Hospital, Salt Lake City, Utah. 5. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 6. Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and. 7. Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high rates of treatment failure in adults. The epidemiology, clinical outcomes, and risk factors for treatment failure associated with MRSA bacteremia in children are poorly understood. METHODS: Multicenter, retrospective cohort study of children ≤18 years hospitalized with MRSA bacteremia across 3 tertiary care children's hospitals from 2007 to 2014. Treatment failure was defined as persistent bacteremia >3 days, recurrence of bacteremia within 30 days, or attributable 30-day mortality. Potential risk factors for treatment failure, including the site of infection, vancomycin trough concentration, critical illness, and need for source control, were collected via manual chart review and evaluated using multivariable logistic regression. RESULTS: Of 232 episodes of MRSA bacteremia, 72 (31%) experienced treatment failure and 23% developed complications, whereas 5 (2%) died within 30 days. Multivariable analysis of 174 children treated with vancomycin with steady-state vancomycin concentrations obtained found that catheter-related infections (odds ratio [OR], 0.36; 95% confidence interval [CI]: 0.13-0.94) and endovascular infections (OR, 4.35; 95% CI: 1.07-17.7) were associated with lower and higher odds of treatment failure, respectively, whereas a first vancomycin serum trough concentration <10 μg/mL was not associated with treatment failure (OR, 1.34; 95% CI, 0.49-3.66). Each additional day of bacteremia was associated with a 50% (95% CI: 26%-79%) increased odds of bacteremia-related complications. CONCLUSIONS: Hospitalized children with MRSA bacteremia frequently suffered treatment failure and complications, but mortality was low. The odds of bacteremia-related complications increased with each additional day of bacteremia, emphasizing the importance of achieving rapid sterilization.
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high rates of treatment failure in adults. The epidemiology, clinical outcomes, and risk factors for treatment failure associated with MRSA bacteremia in children are poorly understood. METHODS: Multicenter, retrospective cohort study of children ≤18 years hospitalized with MRSA bacteremia across 3 tertiary care children's hospitals from 2007 to 2014. Treatment failure was defined as persistent bacteremia >3 days, recurrence of bacteremia within 30 days, or attributable 30-day mortality. Potential risk factors for treatment failure, including the site of infection, vancomycin trough concentration, critical illness, and need for source control, were collected via manual chart review and evaluated using multivariable logistic regression. RESULTS: Of 232 episodes of MRSA bacteremia, 72 (31%) experienced treatment failure and 23% developed complications, whereas 5 (2%) died within 30 days. Multivariable analysis of 174 children treated with vancomycin with steady-state vancomycin concentrations obtained found that catheter-related infections (odds ratio [OR], 0.36; 95% confidence interval [CI]: 0.13-0.94) and endovascular infections (OR, 4.35; 95% CI: 1.07-17.7) were associated with lower and higher odds of treatment failure, respectively, whereas a first vancomycin serum trough concentration <10 μg/mL was not associated with treatment failure (OR, 1.34; 95% CI, 0.49-3.66). Each additional day of bacteremia was associated with a 50% (95% CI: 26%-79%) increased odds of bacteremia-related complications. CONCLUSIONS: Hospitalized children with MRSA bacteremia frequently suffered treatment failure and complications, but mortality was low. The odds of bacteremia-related complications increased with each additional day of bacteremia, emphasizing the importance of achieving rapid sterilization.
Authors: Kerry J Welsh; April N Abbott; Evan M Lewis; Jeanelle M Gardiner; Mark C Kruzel; Cole T Lewis; John F Mohr; Audrey Wanger; Lisa Y Armitige Journal: J Clin Microbiol Date: 2010-01-20 Impact factor: 5.948
Authors: Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Wei Gao; Benjamin P Howden; Paul D R Johnson Journal: Antimicrob Agents Chemother Date: 2013-01-18 Impact factor: 5.191
Authors: Jennifer Le; John S Bradley; William Murray; Gale L Romanowski; Tu T Tran; Natalie Nguyen; Susan Cho; Stephanie Natale; Ivilynn Bui; Tri M Tran; Edmund V Capparelli Journal: Pediatr Infect Dis J Date: 2013-04 Impact factor: 2.129
Authors: J Chase McNeil; Eric Y Kok; Andrea R Forbes; Linda Lamberth; Kristina G Hulten; Jesus G Vallejo; Edward O Mason; Sheldon L Kaplan Journal: Pediatr Infect Dis J Date: 2016-03 Impact factor: 2.129
Authors: Achim J Kaasch; Gavin Barlow; Jonathan D Edgeworth; Vance G Fowler; Martin Hellmich; Susan Hopkins; Winfried V Kern; Martin J Llewelyn; Siegbert Rieg; Jesús Rodriguez-Baño; Matthew Scarborough; Harald Seifert; Alex Soriano; Robert Tilley; M Estée Tőrők; Verena Weiß; A Peter R Wilson; Guy E Thwaites Journal: J Infect Date: 2013-11-16 Impact factor: 6.072
Authors: Vincent Le Moing; François Alla; Thanh Doco-Lecompte; François Delahaye; Lionel Piroth; Catherine Chirouze; Pierre Tattevin; Jean-Philippe Lavigne; Marie-Line Erpelding; Bruno Hoen; François Vandenesch; Xavier Duval Journal: PLoS One Date: 2015-05-28 Impact factor: 3.240
Authors: Eric Y Kok; Jesus G Vallejo; Lauren M Sommer; Louie Rosas; Sheldon L Kaplan; Kristina G Hulten; J Chase McNeil Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Oren Gordon; Nadine Peart Akindele; Christina Schumacher; Ann Hanlon; Patricia J Simner; Karen C Carroll; Anna C Sick-Samuels Journal: Pediatr Qual Saf Date: 2022-06-14
Authors: Michael J Tchou; Heidi Andersen; Eric Robinette; Joel E Mortensen; Eleanor A Powell; Andrea Ankrum; Matthew C Washam; David B Haslam; Joshua D Courter Journal: Pediatr Qual Saf Date: 2019-08-05
Authors: Sarah Grace Gunter; Mary Joyce B Wingler; David A Cretella; Jamie L Wagner; Katie E Barber; Kayla R Stover Journal: Pharmacy (Basel) Date: 2022-01-15